Global Kaposi's sarcoma treatment Market, By Type (Epidemic (AIDS Associated) Kaposi Sarcoma, Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Latrogenic (Transplant-Related) Kaposi Sarcoma), Treatment (HAART, Radiation Therapy, Surgery, Cryosurgery, Chemotherapy, Biological Therapy), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Kaposi's Sarcoma Treatment Market Analysis and Size
With the growing incidence of Kaposi Sarcoma and the increasing number of patients undergoing organ transplantation procedures, patients undergoing organ transplantations are more vulnerable to Kaposi sarcoma. Patients with weakened immune systems by acquired immune deficiency syndrome (AIDS) disease or drugs prescribed post-organ transplantation surgery are highly susceptible to HHV-8. Organ transplant patients are prescribed immunosuppressive agents to prevent their bodies from rejecting the graft, increasing their susceptibility to Kaposi sarcoma-associated herpesvirus (KSHV) infection. The long-term use of these agents surges these patients' risk rate by over 100 times more than the general population.
Data Bridge Market Research analyses a growth rate in the global Kaposi's sarcoma treatment market in the forecast period 2023-2020. The expected CAGR of the global Kaposi's sarcoma treatment market tends to be around 7.00% in the mentioned forecast period. The market was valued at USD 150.7 million in 2022 and would grow to USD 258.93 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Kaposi sarcoma is a type of malignant tumor disease majorly that is associated with skin, mucous membranes, lymph nodes, and other organs. These patches or lesions are generally red or purple. They are made of cancer cells, blood vessels, and blood cells. Human herpesvirus-8 (HHV-8) is predominantly found in the lesion of all patients suffering from Kaposi sarcoma.
Kaposi's Sarcoma Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Epidemic (AIDS Associated) Kaposi Sarcoma, Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Latrogenic (Transplant-Related) Kaposi Sarcoma), Treatment (HAART, Radiation Therapy, Surgery, Cryosurgery, Chemotherapy, Biological Therapy), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany)
|
|
Market Opportunities
|
|
Global Kaposi's Sarcoma Treatment Market Dynamics
Drivers
- Increased Transplantations
As per the records of the Global Observatory on Donation and Transplantation, 1 39,024 organs were transplanted worldwide in 2017 in total, which 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Thus, these transplantations make the patient more susceptible to this sarcoma. Therefore, it boosts the market growth.
- High Strategic Collaborations by Market Players
In recent times, there have been significant changes in market strategies, such as product developments, mergers, and acquisitions. For instance, in May 2019, The U.S. FDA granted breakthrough therapy designation to Celgene's pomalidomide (Pomalyst) for treating patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, along with patients with HIV-negative Kaposi sarcoma. This boosts the growth of the market.
Opportunities
- Rising Demand for HAART
Growing demand for antiretroviral therapies leads to patients' faster recovery. For individuals with Epidemic (AIDS-associated) Kaposi sarcoma, antiretroviral treatment for HIV or AIDS is usually used before other therapies for treating the tumor and reducing the symptoms. HAART is preferred as individual therapy or chemotherapy based on the disease's spread and the patient's symptoms. Thus, this treatment procedure is greatly boosting the growth of the market.
- Rising Healthcare Awareness
Health awareness amongst the population is rising, which results in the prediction that drugs boost market growth. The innovative launches in medications for treating squamous cell carcinoma are expected to prompt the market simultaneously. For instance, in September 2014, F. Hoffmann-La Roche Ltd. Came up with a new Global Access Program for HIV viral load testing in partnership with United Nations Program on HIV/AIDS (UNAIDS), the Clinton Health Access Initiative, the President's Emergency Plan for AIDS Relief, and the Global Fund. The program was totally focused on HIV viral load testing. This creates more opportunities in the market.
Restraints/Challenges
- Lack of Skilled Professionals
A lack of trained healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could limit the growth of the global Kaposi's sarcoma treatment market over a forecast period.
- High Cost
The huge expenditure on treatment methods impede the market growth. For instance, as per the data published by Monash University Malaysia in January 2016, the prices of major drugs that are used for the treatment of Kaposi sarcoma, such as liposomal doxorubicin, liposomal daunorubicin, or paclitaxel along with HAART, are increasing considerably, making them unaffordable for middle- and lower-income group patients.
This global Kaposi's sarcoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Kaposi's sarcoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Kaposi's Sarcoma Treatment Market Scope
The global Kaposi's sarcoma treatment market is segmented on the basis of type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Epidemic (AIDS Associated) Kaposi Sarcoma
- Classic (Mediterranean) Kaposi Sarcoma
- Endemic (African) Kaposi Sarcoma
- Latrogenic (Transplant-Related) Kaposi Sarcoma)
Treatment
- HAART
- Radiation Therapy
- Surgery
- Cryosurgery
- Chemotherapy
- Biological Therapy
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Kaposi's Sarcoma Treatment Market Regional Analysis/Insights
The global Kaposi's sarcoma treatment market is analysed and market size insights and trends are provided by type, treatment, distribution channel and end-user as referenced above.
The major countries covered in the global Kaposi's sarcoma treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the increase in the number of Kaposi's sarcoma patients in the region, coupled with the rise in organ transplants and the intake of immune suppressants.
Asia-Pacific dominates the market due to the increased prevalence of organ transplantation and such therapies in the region. For instance, as per the Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted globally in 2017 which was quite high thus increasing the market share.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Kaposi's Sarcoma Treatment Market Share Analysis
The global Kaposi's sarcoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global Kaposi's sarcoma treatment market.
Key players operating in the global Kaposi's sarcoma treatment market include:
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
Research Methodology: Global Kaposi's Sarcoma Treatment Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-